The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial by Djukanovic, Ratko et al.
&get_box_var;ORIGINAL ARTICLE
The Effect of Inhaled IFN-b on Worsening of Asthma Symptoms
Caused by Viral Infections
A Randomized Trial
Ratko Djukanovic´1, Tim Harrison2, Sebastian L. Johnston3, Flic Gabbay4, Peter Wark5, Neil C. Thomson6,
Robert Niven7, Dave Singh8, Helen K. Reddel9, Donna E. Davies1, Richard Marsden10, Christine Boxall10,
Sarah Dudley10, Vincent Plagnol11, Stephen T. Holgate1, Phillip Monk10, and the INTERCIA Study Group*
1NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences, University of Southampton Faculty of
Medicine, Southampton, United Kingdom; 2Nottingham Respiratory Research Unit, University of Nottingham, Nottingham City Hospital,
Nottingham, United Kingdom; 3Airway Disease Infection Section, National Heart and Lung Institute and Centre for Respiratory Infections, Imperial
College, MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College NHS Trust NIHR Comprehensive Biomedical
Research Centre, London, United Kingdom; 4TranScrip Partners LLP, Reading, United Kingdom; 5Priority Research Centre for Asthma and
Respiratory Diseases, Hunter Medical Research Institute and The University of Newcastle, Newcastle, New South Wales, Australia; 6Institute
of Infection, Immunity and Inflammation, University of Glasgow and Gartnavel General Hospital, Glasgow, United Kingdom; 7Manchester
Academic Health Sciences Centre, University of Manchester and University Hospital of South Manchester UHSM, Manchester, United
Kingdom; 8Respiratory Translational Research Facility, North West Lung Research Centre, Wythenshawe Hospital, Manchester, United
Kingdom; 9Woolcock Institute of Medical Research, University of Sydney, Glebe, Australia; 10Synairgen Research Ltd, Southampton University
Hospital, Southampton, United Kingdom; and 11Genetics Institute, University College London, London, United Kingdom
Abstract
Rationale: Ex vivo, bronchial epithelial cells from people with
asthma are more susceptible to rhinovirus infection caused by
deﬁcient induction of the antiviral protein, IFN-b. Exogenous IFN-b
restores antiviral activity.
Objectives: To compare the efﬁcacy and safety of inhaled IFN-b
with placebo administered to people with asthma after onset of cold
symptoms to prevent or attenuate asthma symptoms caused by
respiratory viruses.
Methods: A total of 147 people with asthma on inhaled
corticosteroids (British Thoracic Society Steps 2–5), with a history
of virus-associated exacerbations, were randomized to 14-day
treatment with inhaled IFN-b (n = 72) or placebo (n = 75)
within 24 hours of developing cold symptoms and were assessed
clinically, with relevant samples collected to assess virus infection
and antiviral responses.
Measurements and Main Results: A total of 91% of randomized
patients developed a deﬁned cold. In this modiﬁed intention-to-treat
population, asthma symptoms did not get clinically signiﬁcantly worse
(mean change in six-item Asthma Control Questionnaire,0.5) and
IFN-b treatment had no signiﬁcant effect on this primary endpoint,
although it enhancedmorning peak expiratoryﬂow recovery (P=0.033),
reduced the need for additional treatment, and boosted innate immunity
as assessed by blood and sputum biomarkers. In an exploratory analysis
of the subsetofmoredifﬁcult-to-treat, Step4-5peoplewithasthma(n=27
IFN-b; n = 31 placebo), Asthma Control Questionnaire-6 increased
signiﬁcantly on placebo; this was prevented by IFN-b (P = 0.004).
Conclusions: Although the trial did not meet its primary endpoint, it
suggests that inhaled IFN-b is a potential treatment for virus-induced
deteriorations of asthma in difﬁcult-to-treat people with asthma and
supports theneedfor further,adequatelypowered, trials in thispopulation.
Clinical trial registered with www.clinicaltrials.gov (NCT 01126177).
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Exacerbations of asthma, the majority
caused by respiratory viruses (1, 2), are
a large unmet medical need, especially in
more severe disease (3–5). People with
asthma are more likely to develop lower
respiratory tract symptoms after an upper
respiratory tract infection (URTI) even
though the frequency and severity of colds
in people with asthma is not higher than
normal (2). Using culture of bronchial
epithelial cells obtained by bronchoscopic
brushings from corticosteroid-treated
people with asthma, we have previously
demonstrated that, when infected with
rhinoviruses (RV), the asthmatic bronchial
epithelium failed to mount an effective
innate immune response involving IFN-b
(6) and IFN-l (7). Suboptimal activation of
antiviral pathways resulted in greater viral
replication and shedding, cytolysis of
epithelial cells, and mediator release (6, 7).
A similar defect exists in asthmatic airway
macrophages (8) and airway cells of
children with asthma (9, 10). Importantly,
epithelial antiviral activity could be
corrected ex vivo by low concentrations of
exogenous IFN-b (6, 11). Some other
studies have been unable to replicate such
differences between people with asthma
and healthy individuals, but these were
conducted in mild, corticosteroid-naive
people with asthma (12) or in those with
well-controlled asthma (13).
To evaluate the clinical relevance of the
IFN-b deﬁciency in asthma and explore the
potential for IFN-b as a treatment for virus-
induced asthma exacerbations, a series of
clinical studies were conducted with inhaled
IFN-b (SNG001; Synairgen Research Ltd,
Southampton, UK) (see online supplement).
A dose-escalating study in volunteers with
asthma showed that nebulized IFN-b (6
mIU) given once daily for 14 days is well
tolerated and enhances innate immune
responses in the airways, as assessed by
several biomarkers of IFN-b–related
antiviral activity (neopterin, IFN-g–induced
protein 10 [IP-10, CXCL10], myxoma
resistance protein 1, and 2’-59 oligoadenylate
synthetase) measured in induced sputum
(see Figure E1 in the online supplement).
This also provided evidence that CXCL10
may be a useful biomarker for clinical
development of IFN-b.
A randomized placebo-controlled trial
of IFN-b administered to people with
asthma with a history of cold-induced
exacerbations was, therefore, conducted to
test the hypothesis that, when delivered by
oral inhalation at the report of an URTI,
IFN-b can prevent or substantially reduce
the increase in asthma symptoms, thereby
providing initial proof of concept for IFN-b
as a potential treatment for virus-induced
exacerbations.
Some of the results of these studies have
been previously reported in the form of an
abstract (14).
Methods
Study Design
This was a randomized, double-blind,
parallel, placebo-controlled trial of IFN-b
(SNG001) (Figures 1 and 2) involving
patients with a history of URTI-induced
exacerbations, to test whether inhaled
Figure 1. CONSORT flow diagram. ACQ = Asthma Control Questionnaire; mITT = modified intention-
to-treat.
At a Glance Commentary
Scientiﬁc Knowledge on the
Subject: People with asthma are more
likely to develop lower respiratory tract
symptoms because of a cold (i.e., an
upper respiratory tract infection), and
there is no speciﬁc antiviral treatment
that can prevent upper respiratory tract
infection–induced asthma exacerbations.
What This Study Adds to the
Field: Although the trial did not meet
its primary endpoint, exploratory
subanalysis of the difﬁcult-to-treat-
subgroup suggests that inhaled IFN-b
enhances innate immunity and may
impact favorably on cold-induced
asthma exacerbations in this patient
population.
ORIGINAL ARTICLE
146 American Journal of Respiratory and Critical Care Medicine Volume 190 Number 2 | July 15 2014
IFN-b can prevent or attenuate worsening
asthma symptoms (deﬁned as a rise in
the six-item Juniper Asthma Control
Questionnaire [ACQ-6] [15]) caused by
respiratory viruses if administered within
24 hours after reporting cold or inﬂuenza
symptoms. The primary endpoint was
deﬁned as the comparison of the mean
change from baseline to Day 8 in ACQ-6 in
the modiﬁed intention-to-treat (mITT)
population (i.e., those patients who fulﬁlled
the Jackson [16] or Predy [17] criteria for
a cold). Patients responded daily to text
message questions about URTI symptoms.
If they met the preset criteria for an URTI,
they attended the research units within
24 hours (Day 1) to begin treatment with
inhaled IFN-b or placebo (randomized in
a 1:1 ratio) given as single daily doses for 14
days. Patients were reviewed on Days 4, 7,
10, 13, and 17 and recorded daily upper and
lower respiratory symptoms and peak
expiratory ﬂow (PEF) measurements at home
(see Table E1 for the full study schedule).
Study Treatments
SNG001 consists of recombinant IFN-b1a
formulated as an aqueous solution
that, unlike some other commercial
preparations, does not contain mannitol or
human serum albumin and is pH neutral.
Patients received 6 mIU of IFN-b or
placebo (formulation buffer without
IFN-b) from a portable mesh nebulizer
delivered over 3–4 minutes (I-neb; Philips
Respironics, Chichester, UK).
Patients
The inclusion criteria for the pretreatment
phase included (1) age 18–65 years, (2)
asthma symptoms for greater than or equal
to 2 years conﬁrmed by history and one
of either FEV1 reversibility to albuterol
(>12% and 200 ml), bronchial
hyperresponsiveness (at screening or
historical), emergency admission, or
attendance at primary care or out-of-hours
clinics for worsening asthma; (3) history of
cold-induced exacerbations and greater
than or equal to one exacerbation suspected
to be caused by a respiratory virus
in the past 24 months requiring oral
corticosteroids and/or antibiotics; and
(4) treatment with regular inhaled
corticosteroids (ICS) (i.e., British Thoracic
Society [BTS] Guidelines Step 2 and above)
(18).
Patients entered the treatment phase
if they fulﬁlled the following criteria: (1)
URTI symptoms within the last 24 hours
presenting as cold symptoms (blocked or
runny nose and a sore or scratchy throat)
or inﬂuenza-like illness (temperature .
37.88C, plus two of either headache, cough,
sore throat, myalgia), (2) patient’s belief
that they have a cold or ﬂu, (3) continued
regular ICS since screening, and (4) post-
bronchodilator FEV1 greater than or equal
to 35% of predicted.
Clinical and Laboratory Assessments
Patients were screened by history, physical
examination, lung function testing, and
bronchial hyperresponsiveness (if asthma
diagnosis required conﬁrmation). To
establish asthma control at screening
baseline, patients completed the ACQ-6,
and over 7 days, recorded twice daily PEF
and responded to asthma symptom
questions from the Asthma Index
Questionnaire (19) (twice daily) and the
Jackson Cold Score questionnaire (JCSQ)
(16) (in the evening) by text message.
After establishing the screening
baseline, patients responded to daily text
messages asking them if they had symptoms
of an URTI (see online supplement). If
the response suggested that patients were
experiencing cold or inﬂuenza symptoms,
patients were telephoned to assess eligibility
for the treatment phase using the JCSQ to
conﬁrm the onset of cold symptoms within
the past 24 hours. For the next 28 days,
beginning on treatment Day 1, the text
messages switched to questions from the
JCSQ and four questions from the Asthma
Index Questionnaire (symptoms of chest
tightness, wheeze, cough, and shortness
of breath, scored 0–3). The ACQ-6 was
completed by telephone interview on Day 1 (as
treatment baseline) and on treatment Day 8.
Nasal lavage was collected during the
ﬁrst week and screened for a panel of
respiratory viruses by quantitative real-time
polymerase chain reaction (qPCR). Sputum
induction was attempted at selected sites
at screening and on treatment Days 4 and
7 to quantify RV virus load and antiviral
biomarkers by qPCR and proinﬂammatory
biomarkers by Luminex (Life Technologies,
Paisley, UK). Blood samples were collected
for measurement of serum CXCL10 by
ELISA and genome-wide gene expression
analysis.
Statistical Analyses
Primary analysis was conducted on data
only from those patients who fulﬁlled the
Jackson (16) or Predy (17) criteria for
Figure 2. Study design. During the pretreatment phase, patients responded to daily text messages
inquiring about symptoms of cold. If the prespecified threshold for symptoms was reached, they
visited the research unit within 24 hours to receive their first dose. Thereafter, patients received their
daily treatment of IFN-b or placebo for a total of 14 days. The primary outcome, a validated shortened
version of the Asthma Control Questionnaire (ACQ-6) (15), was completed during screening,
before treatment began on Day 1, and 7 days later. For details of biologic samples collected, see
METHODS section and Table E1.
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a cold: these patients constituted the
mITT population. All statistical tests were
two-sided with a 5% level of signiﬁcance,
with no adjustments for multiplicity.
The primary hypothesis (that IFN-b is
superior to placebo in respect of the
change from treatment baseline ACQ-6
[Day 1] to Day 8 in the mITT population)
was tested by analysis of covariance,
including terms for pooled site and
baseline value. Sample size calculation,
based on data from a prospective
multicenter study of asthma control
associated with a cold (20), determined
that 56 patients per treatment-arm
provided 80% power to detect a mean
treatment difference of 0.5 in the change
from baseline in ACQ-6 8 days after onset
of a cold, a change accepted as clinically
relevant (21), with a between-patient
standard deviation of 0.93. A planned
masked sample size recalculation (22) was
performed mid-study, resulting in no
required modiﬁcation.
Additional secondary trial endpoints
are provided in the online supplement; the
statistical analysis plan also stated that
exploratory analyses in patient subgroups
deﬁned by asthma severity may be
investigated, although the deﬁnition of
severity was not prespeciﬁed.
Results
Patients
From a total of 319 recruited patients,
147 considered by the investigators to be
developing a cold were randomized into
the treatment phase (ITT population).
Subsequent analysis showed that most (134
patients) went on to develop a cold, as
judged by fulﬁlling either the Jackson
or Predy cold criteria (16); these were,
therefore, treated as the mITT population
(Table 1).
Relationship between Virus Infections
and Asthma Symptoms
Respiratory viruses were detected by qPCR
in nasal lavage in 63% of patients; more than
one virus was detected in some samples.
Most viruses detected were RV (68%),
the rest being adenovirus (3%), bocavirus
(23%), coronavirus (9%), enterovirus
(4%), human metapneumovirus (1%),
parainﬂuenza virus (4%), and respiratory
syncytial virus (3%). Analysis of the time-
course, conducted in the placebo group to
avoid active treatment effects, showed that
both asthma and cold symptoms increased
markedly from screening baseline, peaking
on Day 2 of the treatment phase and
gradually returning to baseline (Figure 3A).
There was a similar trend in the IFN-b
group (Figure 3B). For most patients,
complete sets of asthma symptom scores
were available only from Day 2 (i.e., 1 day
after starting treatment). At presentation,
the URTI (cold) and asthma symptoms
were positively correlated (rs = 0.48; P ,
0.0001) (Figure 3C).
Analysis of Data from the
mITT Population
Because of missing data, 11 subjects were
excluded from analysis of the primary
outcome. Analysis of the effect of treatment
on ACQ-6 from treatment baseline (Day 1)
to Day 8, the primary outcome, showed that
IFN-b was not superior to placebo in the
mITT population (Figure 4A). However,
IFN-b was superior to placebo when
assessing morning PEF (mean between-
Table 1. Patient Characteristics in the mITT Population
Whole mITT BTS Step 2 BTS Step 3 BTS Step 4-5
Placebo
(n = 69)
IFN-b
(n = 65)
Placebo
(n = 15)
IFN-b
(n = 17)
Placebo
(n = 23)
IFN-b
(n = 21)
Placebo
(n = 31)
IFN-b
(n = 27)
Age, yr, mean (range) 39.6 (19–64) 37.0 (19–64) 42.3 (25–58) 33.6 (21–61) 40.3 (19–64) 32.9 (19–57) 37.8 (19–61) 42.2 (23–64)
Sex, male/female, % 30/70 37/63 33/67 24/76 30/70 43/57 29/71 41/59
Atopy status (skin prick test),
atopic/nonatopic/not tested, %*
74/25/1 80/17/3 67/33/0 65/24/12 74/22/4 86/14/0 77/23/0 85/15/0
Smoking status, nonsmoker/smoker, % 87/13 88/12 87/13 88/12 83/17 90/10 90/10 85/15
Smoking history, pack-years, current
smoker/ex-smoker
13.3/8.2 7.8/5.8 22.0/16.3 0.3/2.3 8.1/3.1 14.0/2.0 14.3/3.5 8.5/9.9
Dose of inhaled corticosteroids (before
treatment baseline), mg/d (ﬂuticasone
equivalent), median (range)
400 (100–2,000) 400 (50–2,000) 200 (100–400) 200 (50–400) 200 (100–400) 200 (100–400) 750 (200–2,000)† 800 (200–2,000)†
Prebronchodilator FEV1 at screening,
% of predicted, mean (SD)
90.9 (20.4) 88.9 (19.0) 92.7 (22.7) 94.2 (19.5) 91 (18.8) 91.1 (18.7) 90.0 (21.0) 83.8 (18.5)
Prebronchodilator FEV1 at treatment
baseline, % of predicted, mean (SD)
89.1 (18.5) 88.8 (18.4) 88.7 (19.5) 90.3 (19.9) 89.0 (18.8) 91.1 (17.6) 89.3 (18.5) 86.2 (18.5)
Post-bronchodilator FEV1 at screening,
% of predicted, mean (SD)
98.3 (18.2) 95.6 (17.5) 99.4 (20.3) 101.5 (16.0) 97.0 (17.2) 97.8 (17.3) 98.7 (18.3) 90.1 (17.6)
Post-bronchodilator FEV1 at treatment
baseline, % of predicted, mean (SD)
96.2 (16.7) 94.9 (16.4) 98.1 (16.9) 98.5 (14.1) 95.6 (16.6) 96.2 (15.9) 95.8 (17.1) 91.8 (17.9)
Jackson Cold Score at treatment
baseline (max. 24), score, mean (SD)
8.2 (3.7) 9.1 (4.3) 7.2 (3.5) 8.9 (3.6) 8.8 (4.5) 10.1 (3.5) 8.5 (3.7) 8.1 (4.6)
ACQ-6 at screening (0–6), score,
mean (SD)
1.26 (0.88) 1.20 (0.91) 1.08 (0.69) 0.89 (0.62) 1.19 (0.83) 0.90 (0.82) 1.41 (0.99) 1.63 (1.03)
ACQ-6 at treatment baseline (0–6),
score, mean (SD)
1.57 (0.98) 1.44 (0.95) 1.24 (0.78) 1.23 (0.82) 1.45 (0.97) 1.07 (0.84) 1.82 (1.02) 1.87 (0.97)
Definition of abbreviations: ACQ = Asthma Control Questionnaire; BTS = British Thoracic Society; mITT = modified intention-to-treat.
Patients who fulfilled either the Jackson or Predy criteria (16, 17) for a cold were included in the mITT group. There were no clinically important differences
between patients randomized to receive IFN-b or placebo in respect of any clinical criterion, either when assessing the mITT population as a whole or
when subgrouped by asthma severity, using BTS steps (18, 21).
*Atopy percentages may not always add up to 100% because of rounding.
†Two patients taking 200 mg/day inhaled corticosteroids (fluticasone equivalent) were taking four classes of asthma drug as part of their normal asthma
medication and were, therefore, assigned to the BTS Step 4 subgroup. One subject taking 200 mg/day inhaled corticosteroids (fluticasone equivalent) was
taking oral corticosteroids as part of their normal asthma medication and was assigned to the BTS Step 5 subgroup.
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group difference, 19.47 L/min; 95%
conﬁdence interval [CI], 1.62–37.31; P =
0.033 for area under the curve), with steady
improvement during IFN-b treatment but
an initial decline during the ﬁrst week of
placebo treatment (Figure 4C). There was
also a trend toward reduced sputum RV
load in the active group on Day 4 (mean
between-group difference, 21.20 log10
copies/g; 95% CI, 22.46 to 0.07; P = 0.063)
(Figure 4E).
Assessment of blood and sputum
biomarkers, using a combination of
immunoassay and qPCR, showed changes
consistent with enhanced antiviral
activity and associated attenuation of
proinﬂammatory responses in patients on
IFN-b treatment. Before treatment, serum
levels of the antiviral cytokine, CXCL10,
increased in both the active and placebo-
treated groups relative to screening but
remained elevated over several days only
during IFN-b treatment (Figure 5A),
whereas it fell rapidly on placebo
(differences were signiﬁcant on Days 4, 7,
10, and 13; P = 0.037, 0.001 , 0.001,
, 0.001, respectively, analyzed on the
log scale via analysis of covariance,
including Day 1 as a covariate). There
was a signiﬁcant reduction in the
proinﬂammatory biomarker CCL4
concentration (P = 0.035) in the ﬂuid
phase of sputum from patients receiving
IFN-b on treatment Day 7 (Figure 5B)
and a trend toward reduced CXCL8
concentration (P = 0.109) (Figure 5C),
without any between-group differences in
these biomarkers on Day 4. Analysis of
sputum cell pellets by qPCR showed
signiﬁcantly increased gene expression for
antiviral biomarkers OAS1 (Figure 5D),
Mx1 (Figure 5E), and CXCL10 (Figure 5F)
on Day 7 (P = 0.0003, 0.0001, and 0.0008,
respectively) as a consequence of
treatment, with trends toward increases on
Day 4 for OAS1 and Mx1 (P = 0.07, 0.06,
respectively) but not CXCL10.
Fewer patients who received IFN-b
required additional treatment (i.e.,
oral corticosteroids or antibiotics, for
worsening asthma symptoms during the
treatment period). Including one subject
on placebo who just failed to meet the
mITT JCSQ criteria because of data
missing on Day 1, ﬁve patients receiving
placebo required additional treatment
(four required oral corticosteroids and
one required antibiotics), and one of
these was hospitalized, whereas only
one patient on IFN-b required oral
corticosteroids. Of importance, all the
placebo-treated patients who required
additional treatment were from the
difﬁcult-to-treat patient population
categorized as Step 4 according to the BTS
severity criteria (18), in keeping with these
patients having more severe exacerbations
with viral infections.
Analysis of Patient Subsets Based on
Difﬁculty to Treat
Analysis of the placebo-treated patients
classiﬁed using the BTS criteria showed that
only the difﬁcult-to-treat people with
asthma at Step 4-5 (i.e., not the Step 2 and 3)
had developed a clinically signiﬁcant
increase in asthma symptoms (rise in
ACQ-6 > 0.5) after a cold (Figure 4B),
supporting the observation that this group
was more likely to require additional
corticosteroid or antibiotic treatment.
Further analysis of treatment effects on
the primary outcome in this group of 54
patients showed a mean ACQ-6 increase
of 0.53 in the placebo group (n = 30) and
a decrease of 0.10 in the IFN-b group
(n = 24), a between-group difference of
20.63 (P = 0.004) (Figure 4B, Table 2).
Correspondingly, the percentage of
patients in whom individual changes in
ACQ-6 were greater than or equal to 0.5
was signiﬁcantly lower for IFN-b (17%)
as compared with placebo (50%) (P =
0.012). Similarly, analysis of PEF changes
during the treatment period showed
signiﬁcant IFN-b–related effects in Step
4-5 patients (mean between-group
difference, 31.42 L/min; 95% CI,
3.21–59.63; P = 0.029 for area under
the curve) (Figure 4D, Table 3).
In the Step 2 and 3 subgroups, the
active and placebo treatments were not
statistically different in respect of either
ACQ-6 or PEF. Although the mean rise in
ACQ-6 in the Step 2 subgroup receiving
IFN-b was greater than 0.5, this did not
correspond to the observed changes in PEF,
which were in favor of IFN-b (Table 3).
Analysis of the effect of IFN-b
treatment on CXCL10 responses in the
whole mITT group was also performed
Figure 3. Daily cold and asthma symptom scores in the modified intention-to-treat population.
Symptoms (mean 6 SEM) were analyzed in patients randomized to the placebo arm of the trial (n =
54–69) to avoid any effects of active treatment. (A) This showed that both cold (closed symbol) and
asthma (open symbol) symptoms peaked at presentation, before treatment was initiated, and
declined to baseline in a similar manner over a period of about 17 days. (B) There was a similar trend
in the IFN-b group (n = 51–65). (C) At presentation there was a highly significant monotonic
relationship (Spearman rank correlation = 0.48; P, 0.0001) between upper respiratory tract infection
(cold) and asthma symptoms (n = 61).
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on the BTS Step 4-5 subgroup; this
showed a treatment-related increase in
serum levels of similar signiﬁcance to
those in the entire mITT population
(see Figure E2).
Blood samples collected from patients
in the mITT population provided a unique
opportunity to assess in a post hoc
analysis the effect of treatment on
genome-wide gene expression. Good-
quality data from the analysis were
obtained for 50, 43, and 48 patients from
the Step 4-5 mITT group on Days 1, 4, and
7, respectively. Differentially expressed
gene lists for IFN-b versus placebo
treatment were generated for Days 4 (88
genes) and 7 (94 genes) by selecting probes
that were signiﬁcant at P less than 0.05
and had a fold change of greater than
1.25 following analysis of covariance,
including Day 1 as a covariate. Analysis
of these data using Ingenuity Pathway
Analysis software (Ingenuity Systems
[www.ingenuity.com], Mountain View,
CA) suggested enhanced type I IFN
signaling on both days (Figure 6). After
correction for multiple testing using
a Benjamini-Hochberg procedure, IFN
signaling was the only canonical pathway
that was signiﬁcantly associated with the
dataset (P = 0.015, P = 1.02 3 1025 on
Days 4 and 7, respectively). An upstream
regulator analysis showed predicted
activation of transcriptional factors
associated with type I IFN signaling
(e.g., IFN regulatory factors and STAT1/
STAT2) (23).
Multiple Regression Analysis
A multiple regression analysis was
undertaken to explore whether any of the
baseline assessments seemed to be related
to subsequent changes in ACQ-6 (a score
that reﬂects asthma symptoms over
the previous 7 d) and to any potential
treatment effects. The numbers of
exacerbations in the last 24 months,
screening lung function, BTS step, use of
long-acting b-agonists, and baseline cold
and asthma symptom scores were all
identiﬁed as potentially related to the
change in ACQ-6 from treatment baseline
to Day 8. Based on a subsequent stepwise
regression model, the daily asthma
symptom score on treatment Day 2
(positive slope; the higher the score
the greater the increase in ACQ-6) and
the interaction between study treatment
and BTS step seemed to have the
most inﬂuence on the ACQ-6 change.
Interestingly, daily cold and asthma
symptom scores were worse in the active-
compared with the placebo-treated BTS
Step 2 patients immediately before the
start of treatment. Taking daily asthma
symptom scores at the start of treatment
(Day 2) into account, the estimated
difference in change in ACQ-6 between
IFN-b and placebo reduced in both BTS
Steps 2 (from 0.41 to 0.3; P = 0.29) and 3
(from 0.19 to 0.09; P = 0.73) but increased
in favor of IFN-b in the BTS Step 4-5
group (from 20.63 to 20.76; P , 0.001)
(see Table E3).
Safety
Overall, inhaled IFN-b was well tolerated;
no patient had to stop treatment and
there was little difference between
placebo and IFN-b in the frequency of
treatment-emergent adverse events with
Figure 4. Effect of nebulized IFN-b on clinical outcomes. Analysis of the modified intention-to-treat
population (A) showed that IFN-b treatment (n = 58) did not significantly affect the change in Asthma
Control Questionnaire (ACQ-6) scores (LS mean 6 SEM) at Day 8 (from treatment baseline)
compared with placebo (n = 65). Further analysis of the subgroup with difficult-to-treat asthma
(i.e., British Thoracic Society Step 4-5) (B) showed an increase (LS mean 6 SEM) in ACQ-6 of 0.53 in
the placebo group (n = 30) and a decrease of 0.10 in the IFN-b group (n = 24), a between-group
difference of 20.63 (95% confidence interval [CI], 21.05 to 20.21; P = 0.004). In the whole modified
intention-to-treat population, treatment with IFN-b (closed symbols) resulted in faster recovery of
morning peak expiratory flow (PEF) (C), compared with placebo (open symbols) measured daily at
home (P = 0.033 for area under the curve analysis; n = 56 for placebo; n = 58 for IFN-b; dashed line
represents clinically relevant difference). This improvement was also seen in the British Thoracic
Society Step 4-5 (D) subgroup of patients (P = 0.029 for area under the curve; n = 25 for placebo; n =
22 for IFN-b). Analysis of sputum (E) obtained on Day 4 from patients, in whom rhinovirus was
detected in nasal lavage, showed a trend toward reduced rhinovirus load (P = 0.063) in IFN-b–treated
patients (n = 9) compared with placebo (n = 14).
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the exception of palpitations experienced
by ﬁve subjects on IFN-b and none on
placebo. All were mild and not considered
clinically signiﬁcant and no other cardiac
events were recorded (see Tables E4
and E5).
Discussion
This study is the ﬁrst demonstration of the
ability of a biologic to improve antiviral
responses in patients with asthma that is
also associated with a beneﬁcial clinical
effect. It is, in our view, a good example of
translation of observations of enhanced
innate immune responses from ex vivo
studies (6) into proof of concept clinical
studies. The study suggests that, when given
at the time of reporting an URTI, inhaled
IFN-b can ameliorate the way the airways
of patients with asthma respond to viral
infection. Although the trial did not show
a positive effect on ACQ-6, the primary
outcome, treatment with IFN-b, had
a positive effect on morning lung function
(PEF) and, in parallel, enhanced innate
immunity both systemically and in the
lungs as assessed by serum CXCL10
concentration and induction of genes for
antiviral biomarkers CXCL10, Mx1, and
OAS1 in induced sputum. This was
associated with reduced proinﬂammatory
cytokines in sputum and a trend toward
reduced sputum RV load. Analysis of the
moderate to severe people with asthma
(Step 4 and 5 according to BTS guidelines)
suggested a beneﬁcial clinical effect of
treatment, as shown by a mean 0.63
reduction in ACQ-6 score in patients
treated with IFN-b (P = 0.004 as compared
with those on placebo) that is widely
viewed as being clinically signiﬁcant.
Genome-wide gene expression analysis
using circulating blood cells from this
subset of patients also showed that
treatment with nebulized IFN-b enhanced
systemic innate immunity.
The lack of effect on the primary
outcome is not surprising because the whole
mITT population, which also included mild
people with asthma, did not sustain an
Figure 5. Induction of innate immunity by IFN-b treatment. A more sustained rise (mean 6 SEM) in serum
concentrations of CXCL10 (A) was measured in patients treated with IFN-b (n = 58–65; closed symbols) when
compared with those on placebo (n = 62–66; open symbols). Data were analyzed on the log scale via analysis
of covariance, including Day 1 as a covariate (P = 0.037, 0.001, , 0.001, and , 0.001 for Days 4, 7, 10,
and 13). By comparison with placebo (n = 25) treatment, the concentrations of CCL4 (B) in the sputum
fluid phase measured on Day 7 was significantly (P = 0.035, data were log10 transformed and analyzed by
unpaired t test) lower in patients on IFN-b (n = 24) and there was a trend toward lower CXCL8 (P = 0.109) (C).
Gene expression of antiviral biomarkers OAS1 (D), Mx1 (E), and CXCL10 (F) in sputum cells from patients
treated with IFN-b (n = 16) was significantly higher when compared with placebo (n = 20) on Day 7 (P =
0.0003, 0.0001, and 0.0008 respectively). Data are from patients in the modified intention-to-treat population.
Table 2. Analysis of ACQ-6 during Treatment Period by Asthma Severity (BTS Treatment Step) in the mITT Population
Change in ACQ-6 from Treatment Baseline to Day 8
Whole mITT Step 2 Step 3 Steps 4–5
Placebo IFN-b Placebo IFN-b Placebo IFN-b Placebo IFN-b
N 65 58 14 17 21 17 30 24
Least-squares mean 0.31 0.20 0.12 0.52 0.13 0.32 0.53 20.1
Mean difference (95% CI) 20.11 (20.40 to 0.19) 0.41 (20.15 to 0.97) 0.19 (20.31 to 0.70) 20.63 (21.05 to 20.21)
P value 0.469 0.15 0.45 0.004
Definition of abbreviations: ACQ = Asthma Control Questionnaire; BTS = British Thoracic Society; CI = confidence interval; mITT = modified intention-to-treat.
The ACQ-6 scores were recorded on Days 1 (treatment baseline) and 8 (see METHODS).
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increased ACQ-6 greater than or equal
to 0.5 after cold onset during placebo
treatment, suggesting that, overall, the
exacerbations were not clinically signiﬁcant
in the whole population studied.
Furthermore, prespeciﬁed analysis (as stated
in the statistical analysis plan) of patient
subgroups, with asthma severity classiﬁed by
BTS treatment step criteria (18, 21), showed
Table 3. Analysis of PEF during the Treatment Period by Asthma Severity (BTS Treatment Step) in the mITT Population
Change in Morning PEF (AUC) from Day 2 to 14
Whole mITT Step 2 Step 3 Steps 4–5
Placebo IFN-b Placebo IFN-b Placebo IFN-b Placebo IFN-b
N 56 58 14 16 17 20 25 22
Least-squares mean 25.76 13.71 23.28 2.93 27.39 9.69 26.13 25.29
Mean difference (95% CI) 19.47 (1.62 to 37.31) 6.21 (228.99 to 41.42) 17.08 (214.62 to 48.78) 31.42 (3.21 to 59.63)
P value 0.033 0.727 0.288 0.029
Definition of abbreviations: AUC = area under the curve; BTS = British Thoracic Society; CI = confidence interval; mITT = modified intention-to-treat; PEF =
peak expiratory flow.
Morning PEF was measured daily at home and an area under the curve (AUC) analysis was calculated for change from Day 2 during the treatment period
(beginning on Day 2 and ending on Day 14). The AUC data were then divided by the number of days to provide a clinically meaningful outcome (AUC data
are shown as L/min/day).
Figure 6. Up-regulation of the type I IFN canonical pathway by IFN-b treatment. Analysis of circulating blood cell microarray data using Ingenuity Pathway
Analysis software (Ingenuity Systems [www.ingenuity.com], Mountain View, CA) showed a significant up-regulation of elements (red) of the IFN-b
signaling pathway at both Day 4 and Day 7 after correction for multiple testing using a Benjamini-Hochberg procedure. Data are from patients in the British
Thoracic Society Step 4-5 modified intention-to-treat population.
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a signiﬁcant protective effect of IFN-b in
patients from BTS Steps 4-5 (i.e., those
patients who require more intensive asthma
maintenance treatment). The study,
therefore, suggests that IFN-b treatment
may be most appropriate for the more
difﬁcult to control people with asthma in
whom the underlying disease process is
likely to be more severe, thus requiring
more intensive treatment, and in whom the
risks of exacerbations, health impact, and
treatment costs are greatest (24).
Asthma exacerbations are a major
target for novel therapeutic agents,
including such biologics as omalizumab (25)
and mepolizumab (26). Although effective
at reducing exacerbations, these drugs are
given long-term and systemically, and
are pharmacodynamically unsuitable for
acute administration. ICSs, the mainstay of
asthma treatment, also reduce the rate of
exacerbations, but doubling their dose at
the onset of an exacerbation does not
reduce the severity or rate of recovery of the
exacerbation (27). Thus, nebulized IFN-b
treatment is the ﬁrst therapy acting on the
causal viral pathway that seems able to
prevent worsening of asthma symptoms if
administered shortly after patients become
aware of a cold developing.
IFN-b was selected for clinical
development based on abundant evidence
of its safety in multiple sclerosis (28–31)
and efﬁcacy in preclinical in vitro asthma
studies (6, 11). Accordingly, measurement
of the biomarker CXCL10 in serum and
antiviral biomarkers in sputum cells (OAS1,
Mx1, and CXCL10) demonstrated that
inhaled IFN-b activated local antiviral
defense mechanisms effectively at the
dose and frequency selected for this
trial while, at the same time, attenuating
proinﬂammatory mediators, as judged
by concentrations of CCL4 and CXCL8
measured in airway secretions (sputum).
Additionally, IFN-b treatment resulted
in a modest, but signiﬁcant, induction
of systemic innate immune responses
as judged by the genome-wide gene
expression analysis of blood cells, which
showed signiﬁcant differences in genes
involved in type I IFN signaling. Together
with the sustained and marked elevation
of CXCL10 protein levels in blood, this
suggests that treatment with IFN-b
enhanced innate immunity, which in turn
improved the clinical outcome of the cold.
The trend toward reduced load of RV in
sputum observed with treatment suggests
that better antiviral defenses may result in
faster clearance of RVs. Further studies,
including analysis of other viruses, are
required for more deﬁnitive proof.
It was noted that BTS Step 2 patients
(on low-dose ICS and short-acting
b-agonists) receiving IFN-b had a mean
increase in ACQ-6 of 0.52. However, this
was not signiﬁcantly different to placebo
and analysis of PEF data in this subgroup
did not support a deleterious effect of
IFN-b, mirroring the lack of IFN-b
deﬁciency observed in vitro in mild patients
(12), although this treatment had a positive
effect on both ACQ-6 and PEF in patients
at BTS Step 4-5. Although the number
of patients in the BTS Step 2 group was
relatively small (15 placebo; 17 active), we
cannot exclude the possibility that IFN-b
treatment could have increased asthma
symptoms in a small number of patients.
In summary, this study suggests for the
ﬁrst time that administration of IFN-b by
inhalation can enhance innate immunity
both locally within the lungs and, to
a lesser extent, systemically, thereby
compensating for the IFN-b deﬁciency
that we have previously demonstrated
ex vivo in the epithelium of patients with
moderate-severe asthma (6). The possible
beneﬁcial clinical effect of treatment seen in
patients with moderate-severe asthma
that was associated with this enhancement
suggests that this treatment may impact
favorably on cold-induced asthma
exacerbations. The trial was designed and
powered on the basis of the entire mITT
patient population; therefore, further
adequately powered studies focusing on
more difﬁcult-to-treat people with asthma
are now needed to test the hypothesis that
IFN-b is effective in this high-risk patient
population. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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